Latest Sanofi Stories
- Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in ODYSSEY
TARRYTOWN, N.Y. and PARIS, Aug. 25, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
LifeScienceIndustryResearch.com adds Latest Report on “Market Research Report on Global and Chinese Fexofenadine HCl Industry, 2009-2019” to its store.
Globally, hyaluronic acid viscosupplementation products must rely on clinical efficacy, as healthcare practitioners are not particularly responsive to branding or purchasing incentives, according
Generics Division of Sanofi, Winthrop US, to Market the Drug BRIDGEWATER, N.J., Aug.
First shipment marks a critical step in improving access to treatment worldwide PARIS and SOUTH SAN FRANCISCO, Calif., Aug.
PARIS and VALENCIA, Calif., Aug.
PARIS, July 31, 2014 /PRNewswire/ -- Sanofi, a global and diversified healthcare leader, reports results for the first half of 2014.
TARRYTOWN, N.Y. and PARIS, July 30, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
Primary efficacy endpoints met in all nine new trials of investigational PCSK9 inhibitor TARRYTOWN, N.Y. and PARIS, July 30, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.